Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events

Melody El Chemaly; V. E. McGilligan; Mark Gibson; Matthias  Clauss; Steven Watterson; H. Denis Alexander; AJ Bjourson; Aaron Peace

doi:10.1016/j.acvd.2017.08.002

Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events

Melody El Chemaly
, V. E. McGilligan
, Mark Gibson
, Matthias Clauss
, Steven Watterson
, H. Denis Alexander
, AJ Bjourson
, Aaron Peace

Research output: Contribution to journal › Article › peer-review

36 Downloads (Pure)

Abstract

Summary Tumour necrosis factor alpha converting enzyme (TACE/ADAM17) is a member of the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It regulates many inflammatory processes by cleaving several transmembrane proteins, including tumour necrosis factor alpha (TNFalpha) and its receptors tumour necrosis factor alpha receptor 1 and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several TACE inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes and cancer as well as neurological and immune diseases. This review summarizes the latest discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies that have investigated its expression and protein activity. The multitude of substrates cleaved by TACE make this enzyme an attractive target for therapy and a candidate for biomarker research and development in CAD.

Original language	English
Article number	ACVD-1047
Pages (from-to)	700-711
Number of pages	12
Journal	Archives of Cardiovascular Diseases
Volume	110
Issue number	12
Early online date	31 Oct 2017
DOIs	https://doi.org/10.1016/j.acvd.2017.08.002
Publication status	Published online - 31 Oct 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Atherosclerosis, Transmembrane proteins, TNFα, Biomarker, TACE

Access to Document

10.1016/j.acvd.2017.08.002

Accepted article Author Accepted Manuscript, 385 KB

Investigating known and novel biomarkers for risk stratification in cardiovascular disease
Chemaly, M. (Author), McGilligan, V. (Supervisor), Bjourson, A. (Supervisor) & Peace, A. (Supervisor), May 2018
Student thesis: Doctoral Thesis

File

Cite this

El Chemaly, M., McGilligan, V. E., Gibson, M., Clauss, M., Watterson, S., Alexander, H. D., Bjourson, AJ., & Peace, A. (2017). Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events. Archives of Cardiovascular Diseases, 110(12), 700-711. Article ACVD-1047. Advance online publication. https://doi.org/10.1016/j.acvd.2017.08.002

@article{daa1ab1db5b243319660f4c45a87e2d8,

title = "Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events",

abstract = "Summary Tumour necrosis factor alpha converting enzyme (TACE/ADAM17) is a member of the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It regulates many inflammatory processes by cleaving several transmembrane proteins, including tumour necrosis factor alpha (TNFalpha) and its receptors tumour necrosis factor alpha receptor 1 and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several TACE inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes and cancer as well as neurological and immune diseases. This review summarizes the latest discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies that have investigated its expression and protein activity. The multitude of substrates cleaved by TACE make this enzyme an attractive target for therapy and a candidate for biomarker research and development in CAD.",

keywords = "Atherosclerosis, Transmembrane proteins, TNFα, Biomarker, TACE",

author = "\{El Chemaly\}, Melody and McGilligan, \{V. E.\} and Mark Gibson and Matthias Clauss and Steven Watterson and Alexander, \{H. Denis\} and AJ Bjourson and Aaron Peace",

year = "2017",

month = oct,

day = "31",

doi = "10.1016/j.acvd.2017.08.002",

language = "English",

volume = "110",

pages = "700--711",

journal = "Archives of Cardiovascular Diseases",

publisher = "Elsevier Masson",

number = "12",

}

El Chemaly, M, McGilligan, VE, Gibson, M, Clauss, M, Watterson, S, Alexander, HD, Bjourson, AJ & Peace, A 2017, 'Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events', Archives of Cardiovascular Diseases, vol. 110, no. 12, ACVD-1047, pp. 700-711. https://doi.org/10.1016/j.acvd.2017.08.002

TY - JOUR

T1 - Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events

AU - El Chemaly, Melody

AU - McGilligan, V. E.

AU - Gibson, Mark

AU - Clauss, Matthias

AU - Watterson, Steven

AU - Alexander, H. Denis

AU - Bjourson, AJ

AU - Peace, Aaron

PY - 2017/10/31

Y1 - 2017/10/31

N2 - Summary Tumour necrosis factor alpha converting enzyme (TACE/ADAM17) is a member of the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It regulates many inflammatory processes by cleaving several transmembrane proteins, including tumour necrosis factor alpha (TNFalpha) and its receptors tumour necrosis factor alpha receptor 1 and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several TACE inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes and cancer as well as neurological and immune diseases. This review summarizes the latest discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies that have investigated its expression and protein activity. The multitude of substrates cleaved by TACE make this enzyme an attractive target for therapy and a candidate for biomarker research and development in CAD.

AB - Summary Tumour necrosis factor alpha converting enzyme (TACE/ADAM17) is a member of the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It regulates many inflammatory processes by cleaving several transmembrane proteins, including tumour necrosis factor alpha (TNFalpha) and its receptors tumour necrosis factor alpha receptor 1 and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several TACE inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes and cancer as well as neurological and immune diseases. This review summarizes the latest discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies that have investigated its expression and protein activity. The multitude of substrates cleaved by TACE make this enzyme an attractive target for therapy and a candidate for biomarker research and development in CAD.

KW - Atherosclerosis, Transmembrane proteins, TNFα, Biomarker, TACE

U2 - 10.1016/j.acvd.2017.08.002

DO - 10.1016/j.acvd.2017.08.002

M3 - Article

VL - 110

SP - 700

EP - 711

JO - Archives of Cardiovascular Diseases

JF - Archives of Cardiovascular Diseases

IS - 12

M1 - ACVD-1047

ER -

Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Student theses

Investigating known and novel biomarkers for risk stratification in cardiovascular disease

Cite this